Forvis Mazars Wealth Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Forvis Mazars Wealth Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-17,449	Closed	-$51K	–	192
2015 Q2	$51K	Sell	17,449 -112	-0.6%	-$434	0.01%	180
2015 Q1	$70K	Buy	+17,561	New	+$60.8K	0.01%	187

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return